AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28602417 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiation therapy (25 Gy in 5 fractions, arm 1)
Number of subjects: 61
Study 28602417 — intervention group
Group type: COMPARATOR
Intervention: Commonly used radiation therapy (40 Gy in 15 fractions, arm 2)
Number of subjects: 61
Study 26261149 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of dental materials in patients with oral lichenoid lesions (13 patients consented to removal)
Number of subjects: 45
Study 26261149 — intervention group
Group type: COMPARATOR
Intervention: Patch tests for dental restoration materials
Number of subjects: 45
Study 24024324 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoction for reinforcing lung Qi and argon helium lancet
Number of subjects: 76
Study 24024324 — intervention group
Group type: COMPARATOR
Intervention: Argon helium lancet only (Control)
Number of subjects: 76
Study 21373180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-cues video
Number of subjects: 26
Study 21373180 — intervention group
Group type: COMPARATOR
Intervention: Neutral video (nature scenes)
Number of subjects: 26
Study 17828390 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 40,000 IU
Number of subjects: 2
Study 17828390 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 2
Study 16317311 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-100 mg/day)
Number of subjects: 235
Study 16317311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 14962907 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antithrombotic prophylaxis
Number of subjects: 0
Study 14962907 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11054013 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical furosemide after surgical treatment
Number of subjects: 104
Study 11054013 — intervention group
Group type: COMPARATOR
Intervention: No treatment after surgical treatment (Control)
Number of subjects: 104
Study 9296823 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocauthery plus immunotherapy
Number of subjects: 40
Study 9296823 — intervention group
Group type: COMPARATOR
Intervention: Local electrocauthery over turbinate processes alone
Number of subjects: 40
Study 8437304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhaler
Number of subjects: 286
Study 8437304 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 286
Study 3614615 — intervention group
Group type: COMPARATOR
Intervention: 10 mg diazepam
Number of subjects: 12
Study 29054485 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRS) at p-threshold of 1e-07
Number of subjects: 730
Study 29054485 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic burden
Number of subjects: 730
Study 29054485 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS
Number of subjects: 730
Study 29054485 — intervention group
Group type: EXPERIMENTAL
Intervention: Set-based analyses
Number of subjects: 730
Study 26703894 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (100% oxygen at 2.4 ATA)
Number of subjects: 84
Study 26703894 — intervention group
Group type: COMPARATOR
Intervention: Sham control (21% oxygen at 1.3 ATA)
Number of subjects: 84
Study 24919694 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo of an overweight model
Number of subjects: 563
Study 24919694 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo of a morbidly obese model
Number of subjects: 563
Study 24919694 — intervention group
Group type: COMPARATOR
Intervention: No photo
Number of subjects: 563
Study 22456820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive ultrasound imaging (5 scans throughout pregnancy)
Number of subjects: 2834
Study 22456820 — intervention group
Group type: COMPARATOR
Intervention: Regular ultrasound imaging (1 scan at 18 weeks)
Number of subjects: 2834
Study 20860506 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced-support group (telephone intervention)
Number of subjects: 174120
Study 20860506 — intervention group
Group type: COMPARATOR
Intervention: Usual-support group (no enhanced intervention)
Number of subjects: 174120
Study 18754819 — intervention group
Group type: EXPERIMENTAL
Intervention: Pause-and-perfect training method
Number of subjects: 28
Study 18754819 — intervention group
Group type: COMPARATOR
Intervention: Traditional observation method
Number of subjects: 28
Study 15627731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound elasticity imaging in ESRD subjects
Number of subjects: 12
Study 15627731 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound elasticity imaging in healthy controls
Number of subjects: 12
Study 15627731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound elasticity imaging in transplant renal cortical strain for subject with CAN
Number of subjects: 12
Study 12576316 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab plus CHOP)
Number of subjects: 399
Study 12576316 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 399
Study 10642731 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated diffusion-weighted images and ADC maps with voxel-based parameter sets of relaxation times (T1, T2)
Number of subjects: 0
Study 10642731 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 relaxation incorporated into the data set
Number of subjects: 0
Study 10642731 — intervention group
Group type: EXPERIMENTAL
Intervention: T2- or diffusion-weighted images combined with ADC maps
Number of subjects: 0
Study 8878069 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (0.25‐0.5 U/kg/week)
Number of subjects: 15
Study 8878069 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 15
Study 1959783 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin in combination with epirubicin
Number of subjects: 40
Study 1959783 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin in combination with etoposide
Number of subjects: 40
Study 6318351 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐Profenid 150 mg (two daily doses of 150 mg)
Number of subjects: 20
Study 6318351 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (two daily doses of 50 mg)
Number of subjects: 20
Study 30658705 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (0.048 mA/cm2)
Number of subjects: 40
Study 30658705 — intervention group
Group type: COMPARATOR
Intervention: Placebo tDCS
Number of subjects: 40
Study 30658705 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 40
Study 29429593 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF/G (beclometasone dipropionate, formoterol fumarate, and glycopyrronium) 87 μg/5 μg/9 μg, two inhalations per day
Number of subjects: 1532
Study 29429593 — intervention group
Group type: COMPARATOR
Intervention: IND/GLY (indacaterol plus glycopyrronium) 85 μg/43 μg, one inhalation per day
Number of subjects: 1532
Study 27614902 — intervention group
Group type: EXPERIMENTAL
Intervention: State EITC supplements
Number of subjects: 0
Study 27614902 — intervention group
Group type: EXPERIMENTAL
Intervention: State EITC supplements for a family of three
Number of subjects: 0
Study 23835773 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga Respiratory Training (YRT)
Number of subjects: 81
Study 23835773 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Threshold Training (ITT)
Number of subjects: 81
Study 23835773 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 81
Study 22894937 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental instruction followed by practice in speeding responses
Number of subjects: 0
Study 22894937 — intervention group
Group type: COMPARATOR
Intervention: Experimental instruction alone
Number of subjects: 0
Study 22894937 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-dissociation analysis
Number of subjects: 0
Study 20205966 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally glycosylated GMP (3.5% NeuNAc, 1.5% Gal)
Number of subjects: 20
Study 20205966 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated GMP (12.0% NeuNAc, 4.2% Gal)
Number of subjects: 20
Study 20205966 — intervention group
Group type: EXPERIMENTAL
Intervention: GMP-depleted whey protein concentrate
Number of subjects: 20
Study 20205966 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 20
Study 18602526 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril treatment for 3 months
Number of subjects: 621
Study 18602526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 621
Study 15809548 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilator (albuterol/ipratropium bromide solution)
Number of subjects: 30
Study 15809548 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study 11823666 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hyperthermia (maximum temperature within the first 24 hours ranging from 37.2 degrees C to 39.3 degrees C)
Number of subjects: 300
Study 11823666 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the curve for temperatures >37 degrees C
Number of subjects: 300
Study 10965009 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus intrathecal injections of 50 microg of baclofen
Number of subjects: 7
Study 10965009 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus intrathecal injections of 75 microg of baclofen
Number of subjects: 7
Study 10965009 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intrathecal administration of baclofen via subcutaneous pump
Number of subjects: 7
Study 10965009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8791041 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg intravenous)
Number of subjects: 10
Study 1611810 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg midazolam intravenously in 15 minutes
Number of subjects: 8
Study 1611810 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg alpha-hydroxymidazolam intravenously in 15 minutes
Number of subjects: 8
Study 1611810 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg midazolam orally
Number of subjects: 8
Study 1611810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6231156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous saralasin (0.5, 1 and 5 micrograms min‐1 kg‐1) in tetraplegic patients
Number of subjects: 15
Study 6231156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous saralasin (5 micrograms kg‐1 min‐1) in tetraplegic patients after alpha‐adrenoceptor blockade with thymoxamine (1 mg kg‐1 h‐1)
Number of subjects: 15
Study 6231156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous saralasin in both groups (tetraplegic patients and normal subjects)
Number of subjects: 15
Study 6231156 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal plasma renin activity in both groups
Number of subjects: 15
Study 29623135 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Oxygen Therapy (HFO)
Number of subjects: 0
Study 29623135 — intervention group
Group type: COMPARATOR
Intervention: Mask Oxygen Therapy
Number of subjects: 0
Study 27015606 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate triple therapy (IT)
Number of subjects: 0
Study 27015606 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate etanercept (IE)
Number of subjects: 0
Study 27015606 — intervention group
Group type: COMPARATOR
Intervention: Step-up triple therapy (ST)
Number of subjects: 0
Study 27015606 — intervention group
Group type: COMPARATOR
Intervention: Step-up etanercept (SE)
Number of subjects: 0
Study 24506739 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco‐NPDS
Number of subjects: 52
Study 24506739 — intervention group
Group type: COMPARATOR
Intervention: NPDS
Number of subjects: 52
Study 23610856 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect videolaryngoscopy
Number of subjects: 80
Study 23610856 — intervention group
Group type: COMPARATOR
Intervention: Classic direct laryngoscopy
Number of subjects: 80
Study 23610856 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect videolaryngoscopy with beta blockade
Number of subjects: 80
Study 20670756 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 11479
Study 20670756 — intervention group
Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 11479
Study 18586124 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (supervised, group program, 6 exercises using weight machines, performed twice a week for 10 weeks, 2-3 sets of 10-12 repetitions until fatigue)
Number of subjects: 20
Study 18586124 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 20
Study 18586124 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 20
Study 16204706 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET
Number of subjects: 81
Study 16204706 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 81
Study 12006902 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0
Study 12006902 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 0
Study 12006902 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 0
Study 12006902 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 0
Study 12006902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11994246 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 301
Study 9661603 — intervention group
Group type: EXPERIMENTAL
Intervention: pamidronate (APD) 30 mg i.v. every 3 months for 2 yr
Number of subjects: 55
Study 9661603 — intervention group
Group type: COMPARATOR
Intervention: placebo (placebo/T4)
Number of subjects: 55
Study 7663782 — intervention group
Group type: EXPERIMENTAL
Intervention: Survanta (n = 6)
Number of subjects: 23
Study 7663782 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveofact (n = 8)
Number of subjects: 23
Study 2699997 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (2 grams added to dialysis bath for three months) during acetate hemodialysis
Number of subjects: 9
Study 2699997 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (2 grams added to dialysis bath for three months) during bicarbonate hemodialysis
Number of subjects: 9
Study 2699997 — intervention group
Group type: COMPARATOR
Intervention: Placebo during acetate hemodialysis
Number of subjects: 9
Study 2699997 — intervention group
Group type: COMPARATOR
Intervention: Placebo during bicarbonate hemodialysis
Number of subjects: 9
Study 832179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular atropine as the only premedication
Number of subjects: 120
Study 832179 — intervention group
Group type: COMPARATOR
Intervention: Intravenous atropine at the time of induction of anaesthesia
Number of subjects: 120
Study 6757458 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulphamethoxazole
Number of subjects: 0
Study 6757458 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 0
Study 31047905 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus urodynamics (UDS)
Number of subjects: 820
Study 31047905 — intervention group
Group type: COMPARATOR
Intervention: Routine, noninvasive tests (control)
Number of subjects: 820
Study 29534997 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months of monthly degarelix (first dose 240 mg, subsequent doses 80 mg per month)
Number of subjects: 90
Study 29534997 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 months of monthly degarelix (first dose 240 mg, subsequent doses 80 mg per month)
Number of subjects: 90
Study 29534997 — intervention group
Group type: COMPARATOR
Intervention: 4 months of monthly degarelix
Number of subjects: 90
Study 29534997 — intervention group
Group type: COMPARATOR
Intervention: 10 months of monthly degarelix
Number of subjects: 90
Study 26728893 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2327 (3 mg BID)
Number of subjects: 22
Study 26728893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 25109239 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (200-500 mg/day)
Number of subjects: 295
Study 25109239 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (400-1,200 mg/day)
Number of subjects: 295
Study 25109239 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 295
Study 25109239 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 295
Study 23197752 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 10 mg
Number of subjects: 249
Study 23197752 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg
Number of subjects: 249
Study 23197752 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 40 mg
Number of subjects: 249
Study 23197752 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 80 mg
Number of subjects: 249
Study 23197752 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant (all doses combined)
Number of subjects: 249
Study 23197752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 20215976 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein supplementation
Number of subjects: 62
Study 20215976 — intervention group
Group type: COMPARATOR
Intervention: Control foods
Number of subjects: 62
Study 18557167 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (30 mg/kg over 10 minutes, then 10 mg/kg/hr throughout surgery)
Number of subjects: 50
Study 18557167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15784063 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (300 mg/day)
Number of subjects: 210
Study 15784063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 12641685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg.kg(‐1)
Number of subjects: 80
Study 12641685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg.kg(‐1) + Midazolam 0.1 mg.kg(‐1)
Number of subjects: 80
Study 12641685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg.kg(‐1) + Midazolam 0.2 mg.kg(‐1)
Number of subjects: 80
Study 12641685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg.kg(‐1) + Midazolam 0.2 mg.kg(‐1)
Number of subjects: 80
Study 12641685 — intervention group
Group type: COMPARATOR
Intervention: Halothane induction (comparison group)
Number of subjects: 80
Study 10594542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prednisolone 80 mg
Number of subjects: 18
Study 10594542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8701413 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant thromboplastin (rTF, ISI = 0.82)
Number of subjects: 67
Study 8701413 — intervention group
Group type: COMPARATOR
Intervention: Rabbit thromboplastin (RT, ISI = 1.46)
Number of subjects: 67
Study 2072220 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin therapy only
Number of subjects: 30
Study 2072220 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin and prednisone
Number of subjects: 30
Study 2072220 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 6134298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral temazepam (20 mg)
Number of subjects: 6
Study 6134298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30447052 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistin concentration ≥ 11.4 ng/mL
Number of subjects: 284
Study 30447052 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher resistin levels
Number of subjects: 284
Study 30447052 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistin concentration above 11 ng/mL
Number of subjects: 284
Study 30447052 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate predictors
Number of subjects: 284
Study 30447052 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistin
Number of subjects: 284
Study 30308428 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV-ER (extended-release levetiracetam)
Number of subjects: 0
Study 30308428 — intervention group
Group type: COMPARATOR
Intervention: LEV-IR (immediate-release levetiracetam)
Number of subjects: 0
Study 30308428 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV-ER
Number of subjects: 0
Study 30308428 — intervention group
Group type: COMPARATOR
Intervention: LEV-IR
Number of subjects: 0
Study 27468543 — intervention group
Group type: EXPERIMENTAL
Intervention: A & As particle 15.2 g/day
Number of subjects: 158
Study 27468543 — intervention group
Group type: COMPARATOR
Intervention: losartan 50 mg/day
Number of subjects: 158
Study 24633208 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine/lamivudine plus abacavir (cABC arm)
Number of subjects: 600
Study 24633208 — intervention group
Group type: EXPERIMENTAL
Intervention: nevirapine (cNVP arm)
Number of subjects: 600
Study 24633208 — intervention group
Group type: COMPARATOR
Intervention: cNVP arm
Number of subjects: 600
Study 24633208 — intervention group
Group type: COMPARATOR
Intervention: cABC arm
Number of subjects: 600
Study 22926008 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered tailored intervention
Number of subjects: 556
Study 22926008 — intervention group
Group type: COMPARATOR
Intervention: Non-tailored print material (American Cancer Society brochure)
Number of subjects: 556
Study 20003628 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of processing intervention
Number of subjects: 2802
Study 20003628 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 2802
Study 20003628 — intervention group
Group type: COMPARATOR
Intervention: Memory intervention
Number of subjects: 2802
Study 20003628 — intervention group
Group type: COMPARATOR
Intervention: Reasoning intervention
Number of subjects: 2802
Study 17914073 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 342
Study 17914073 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate
Number of subjects: 342